Aurinia Pharmaceuticals Net Worth
Aurinia Pharmaceuticals Net Worth Breakdown | AUPH |
Aurinia Pharmaceuticals Net Worth Analysis
Aurinia Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Aurinia Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Aurinia Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Aurinia Pharmaceuticals' net worth analysis. One common approach is to calculate Aurinia Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Aurinia Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Aurinia Pharmaceuticals' net worth. This approach calculates the present value of Aurinia Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Aurinia Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Aurinia Pharmaceuticals' net worth. This involves comparing Aurinia Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Aurinia Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Aurinia Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Aurinia Pharmaceuticals' net worth research are outlined below:
| Aurinia Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 175.51 M. Net Loss for the year was (78.02 M) with profit before overhead, payroll, taxes, and interest of 83.38 M. | |
| Aurinia Pharmaceuticals currently holds about 391.51 M in cash with (33.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
| Aurinia Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from bizjournals.com: Aurinia Pharmaceuticals laying off dozens in Montgomery County |
Aurinia Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Aurinia Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aurinia Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Aurinia Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aurinia Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aurinia Pharmaceuticals backward and forwards among themselves. Aurinia Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Aurinia Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-09-30 | 995.7 K | Charles Schwab Investment Management Inc | 2024-09-30 | 744 K | Citigroup Inc | 2024-09-30 | 654.2 K | Trexquant Investment Lp | 2024-09-30 | 583 K | Aqr Capital Management Llc | 2024-09-30 | 568.3 K | Segall Bryant & Hamill | 2024-09-30 | 562.8 K | Sg Americas Securities, Llc | 2024-09-30 | 547.7 K | Citadel Advisors Llc | 2024-09-30 | 546.9 K | Jpmorgan Chase & Co | 2024-09-30 | 502.8 K | Blackrock Inc | 2024-06-30 | 9.3 M | Armistice Capital, Llc | 2024-09-30 | 8.2 M |
Follow Aurinia Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.29 B.Market Cap |
|
Project Aurinia Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.14) | (0.15) | |
| Return On Capital Employed | (0.19) | (0.20) | |
| Return On Assets | (0.14) | (0.15) | |
| Return On Equity | (0.21) | (0.22) |
When accessing Aurinia Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Aurinia Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Aurinia Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Aurinia Pharmaceuticals' management efficiency
Aurinia Pharmaceuticals has return on total asset (ROA) of (0.0216) % which means that it has lost $0.0216 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0578) %, meaning that it created substantial loss on money invested by shareholders. Aurinia Pharmaceuticals' management efficiency ratios could be used to measure how well Aurinia Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.15. The current Return On Capital Employed is estimated to decrease to -0.2. As of now, Aurinia Pharmaceuticals' Total Current Assets are increasing as compared to previous years. The Aurinia Pharmaceuticals' current Intangible Assets is estimated to increase to about 7 M, while Return On Tangible Assets are projected to decrease to (0.15).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.64 | 2.51 | |
| Tangible Book Value Per Share | 2.60 | 2.47 | |
| Enterprise Value Over EBITDA | (21.20) | (20.14) | |
| Price Book Value Ratio | 3.41 | 3.58 | |
| Enterprise Value Multiple | (21.20) | (20.14) | |
| Price Fair Value | 3.41 | 3.58 | |
| Enterprise Value | 1.4 B | 1.5 B |
Effective leadership at Aurinia Pharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Enterprise Value Revenue 4.6508 | Revenue 220.4 M | Quarterly Revenue Growth 0.243 | Revenue Per Share 1.536 | Return On Equity (0.06) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aurinia Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aurinia Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aurinia Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aurinia Pharmaceuticals Corporate Filings
F4 | 9th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 12th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Aurinia Pharmaceuticals Earnings per Share Projection vs Actual
Aurinia Pharmaceuticals Corporate Management
| Chris Hays | VP Marketing | Profile | |
| Premchandran Ramiya | Senior Chain | Profile | |
| Joseph CPA | Chief Officer | Profile | |
| Ann Daus | Senior Quality | Profile | |
| Andrea Christopher | Head Relations | Profile | |
| Michael Martin | Chief Officer | Profile |
Already Invested in Aurinia Pharmaceuticals?
The danger of trading Aurinia Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aurinia Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aurinia Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aurinia Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.536 | Quarterly Revenue Growth 0.243 | Return On Assets (0.02) | Return On Equity (0.06) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.